Pharmacogenomics In Asthma For Predication, Mechanism And Endotyping

Overview

About this study

The purpose of this study is to collect data to try to identify biomarkers that have the potential to personalize asthma therapeutic response to these biologic agents and provide detailed understanding about the mechanisms underlying asthma that may one day be relevant to the further treatment or prevention of this disease in the future.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Male and female subjects of all ethnicities.
  • T2 high/high eosinophil and T2 low moderate-to-severe asthmatics..
  • FEV1 < 80% predicted after a drug withhold.
  • Age 18-65.
  • Nonsmoker with < 5 pack years of prior smoking if < 45 years old and < 10 pack years if age > 45.

Exclusion Criteria:

  • Other lung diseases.
  • Inability to perform required testing including adequate sputum induction at baseline.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/24/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Eugene Bleecker, M.D.

Open for enrollment

Contact information:

Karalyn Folmes

4803014298

folmes.karalyn@mayo.edu

More information

Publications

Publications are currently not available